Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in Oncology

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author BARIANI, Giovanni M. FMUSP-HC
FERRARI, Anezka C. R. de Celis FMUSP-HC
HOFF, Paulo M. FMUSP-HC
KRZYZANOWSKA, Monika K.
RIECHELMANN, Rachel P. FMUSP-HC
dc.date.issued 2013
dc.identifier.citation JOURNAL OF CLINICAL ONCOLOGY, v.31, n.18, p.2289-2295, 2013
dc.identifier.issn 0732-183X
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/1905
dc.description.abstract Purpose Growing participation by industry in cancer research has resulted in increased reporting of conflicts of interest (COI). We aimed to test any association between authors' conclusions and self-reported COI or trial sponsorship in cancer studies. Methods Editorials and related phase III trials published in six clinical oncology journals in the last 3.5 years were analyzed independently by two investigators who classified study conclusions according to authors' endorsement of the experimental therapy. Logistic regression multivariable models were used to assess predictors of favorable conclusions of editorialists and of phase III authors. Results From January 2008 to October 2011, 1,485 articles were retrieved: 150 phase III trials and 150 editorials were eligible. Among the phase III trials, 82 (54.7%) had positive results, and 78 (52.0%) were entirely or partially funded by industry. Any COI were disclosed in 103 phase III trials (68.7%) and in 71 editorials (47.3%). Multivariable analysis showed that phase III trial results were the only significant predictor for a positive conclusion by trial authors (odds ratio [OR], 92.2; 95% CI, 19.7 to 431.6; P < .001). Sponsorship did not predict for positive conclusion by phase III authors (OR, 0.86; 95% CI, 0.3 to 2.5; P = .788). The only factor associated with positive conclusions by editorial authors was a positive conclusion by phase III trial authors (OR, 36.3; 95% CI, 6.8 to 194.2; P < .001). Conclusion The interpretation of recently published phase III cancer trials by their authors or by editorialists was not influenced by financial relationships or industry sponsorship. Increased awareness of COI policies may have led to more integrity in cancer research reporting. (C) 2013 by American Society of Clinical Oncology
dc.language.iso eng
dc.publisher AMER SOC CLINICAL ONCOLOGY
dc.relation.ispartof Journal of Clinical Oncology
dc.rights restrictedAccess
dc.subject.other clinical-trials; economic-analyses; financial relationships; industry sponsorship; cancer trials; disclosure; agreement
dc.title Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in Oncology
dc.type article
dc.rights.holder Copyright AMER SOC CLINICAL ONCOLOGY
dc.description.group LIM/24
dc.identifier.doi 10.1200/JCO.2012.46.6706
dc.identifier.pmid 23630201
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author BARIANI, Giovanni M.:HC:ICESP
hcfmusp.author FERRARI, Anezka C. R. de Celis:HC:ICESP
hcfmusp.author HOFF, Paulo M.:FM:MDR
hcfmusp.author RIECHELMANN, Rachel P.:HC:ICESP
hcfmusp.author.external · KRZYZANOWSKA, Monika K.:Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
hcfmusp.origem.id 2-s2.0-84882968646
hcfmusp.origem.id WOS:000320446700014
hcfmusp.publisher.city ALEXANDRIA
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454
· Booth CM, 2008, J CLIN ONCOL, V26, P5458, DOI 10.1200/JCO.2008.16.5456
· Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209
· Buchkowsky SS, 2004, ANN PHARMACOTHER, V38, P579, DOI 10.1345/aph.1D267
· COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
· Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2
· Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453
· Gardner A, 2007, INT J HEALTH SERV, V37, P591, DOI 10.2190/33N9-23T2-K72T-2LLK
· GEORGE B, 2007, J CLIN ONCOL, V25, pS355
· Hampson LA, 2007, J CLIN ONCOL, V25, P3609, DOI 10.1200/JCO.2006.09.3633
· Hartmann M, 2003, BRIT J CANCER, V89, P1405, DOI 10.1038/sj.bjc.6601308
· Jang S, 2011, AM J CLIN ONCOL-CANC, V34, P524, DOI 10.1097/COC.0b013e3181f4799b
· Kesselheim AS, 2012, CANCER-AM CANCER SOC, V118, P188, DOI 10.1002/cncr.26237
· Knox KS, 2000, ANN ONCOL, V11, P1591, DOI 10.1023/A:1008309817708
· LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
· Lerner TG, 2012, CONTEMP CLIN TRIALS, V33, P1019, DOI 10.1016/j.cct.2012.05.011
· Lexchin J, 2003, BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167
· Lexchin J, 2012, SCI ENG ETHICS, V18, P247, DOI 10.1007/s11948-011-9265-3
· Peppercorn J, 2007, CANCER, V109, P1239, DOI 10.1002/cncr.22528
· RIECHELMANN RP, J CLIN ONCOL S, V25, pS329
· Riechelmann RP, 2007, J CLIN ONCOL, V25, P4642, DOI 10.1200/JCO.2007.11.2482
· Rose SL, 2010, J CLIN ONCOL, V28, P1316, DOI 10.1200/JCO.2008.21.6606
· SCHNEIDER N, 2010, J PUBLIC HLTH, V18, P597, DOI 10.1007/s10389-010-0350-x
· THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812
· Valachis A, 2012, J CLIN ONCOL, V30, P1316, DOI 10.1200/JCO.2011.38.6078
· *AM SOC CLIN ONC, ASCOS POL SAF REL IN
· *BBC NEWS US CAN, BBC NEWS US CANADA
· *J NAT CANC I FORM, FORMS CONFL INT
· 1997, ANN INTERN MED, V126, P36
dc.description.index MEDLINE
hcfmusp.citation.scopus 23
hcfmusp.citation.wos 25
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Canadá


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics